Commitment to Clinical Trial Diversity
Building an inclusive clinical trials infrastructure is an important step toward combatting health inequities and racial disparities in brain health.
Otsuka and Lundbeck announce decision to continue phase III clinical trial evaluating brexpiprazole for treatment of agitation in patients with Alzheimer's-type dementia
Otsuka Pharmaceutical Co., Ltd. (Otsuka) and H. Lundbeck A/S (Lundbeck) announce the decision to continue the recruitment of patients in the phase III clinical trial of brexpiprazole in the treatment of agitation in patients with dementia of the Alzheimer's type (NCT03548584).
Empowering Providers and Patients to Gain Control of an Underdiagnosed Disorder Often Seen with Parkinson’s Disease
Lundbeck offers tools for patients and healthcare providers to identify symptoms of nOH.
Persevering to Power Brain Health Breakthroughs
Gary O’Neill, site head at our Lundbeck La Jolla Research Center, discusses what it takes to persist in the challenging neuroscience space and how learnings from the COVID-19 pandemic could advance breakthroughs in other areas.